Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Grigg

Showing results (51-60 of 132) with videos related to

Pageof 14
Sort By:
Asia-Pacific Journal of Clinical Oncology|April 20, 2010
Mentoring in the management of hematological malignanciesCraig Underhill, Alison Koschel, Jeffrey Szer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2007
Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemiaDeborah White, Verity Saunders, Andrew Grigg, et al.
Blood|April 20, 2002
High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistanceSusan Branford, Zbigniew Rudzki, Sonya Walsh, et al.
Cancer|October 22, 2008
A multicenter phase 2 study of risk-adjusted salvage chemotherapy incorporating vinorelbine and gemcitabine for relapsed and refractory lymphomaSant-Rayn Pasricha, Andrew Grigg, John Catalano, et al.
Leukemia & Lymphoma|May 9, 2008
A phase II study of liposomal daunorubicin, in combination with cyclophosphamide, vincristine and prednisolone, in elderly patients with previously untreated aggressive non-Hodgkin lymphomaPaul L R Mitchell, Paula Marlton, Andrew Grigg, et al.
British Journal of Haematology|July 22, 2014
A multi-centre, single-arm, open-label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R-ITP1000 study)Huyen Tran, Tim Brighton, Andrew Grigg, et al.
The Journal of Antimicrobial Chemotherapy|March 19, 2010
Pharmacoeconomic evaluation of voriconazole versus posaconazole for antifungal prophylaxis in acute myeloid leukaemiaDaoud Al-Badriyeh, Monica Slavin, Danny Liew, et al.
Annals of Hematology|February 17, 2016
Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern eraAzim Jalali, Francis J Ha, Geoff Chong, et al.
Leukemia & Lymphoma|July 26, 2016
Busulfan is effective second-line therapy for older patients with Philadelphia-negative myeloproliferative neoplasms intolerant of or unresponsive to hydroxyureaGenevieve Douglas, Claire Harrison, Cecily Forsyth, et al.
Annals of Hematology|July 28, 2018
The pharmacokinetics and pharmacodynamics of busulfan when combined with melphalan as conditioning in adult autologous stem cell transplant recipientsAbbey Willcox, Eric Wong, Christa Nath, et al.
Pageof 14

Showing results (51-60 of 132) with videos related to

Sort By:
Pageof 14
Asia-Pacific Journal of Clinical Oncology|April 20, 2010
Mentoring in the management of hematological malignanciesCraig Underhill, Alison Koschel, Jeffrey Szer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2007
Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemiaDeborah White, Verity Saunders, Andrew Grigg, et al.
Blood|April 20, 2002
High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistanceSusan Branford, Zbigniew Rudzki, Sonya Walsh, et al.
Cancer|October 22, 2008
A multicenter phase 2 study of risk-adjusted salvage chemotherapy incorporating vinorelbine and gemcitabine for relapsed and refractory lymphomaSant-Rayn Pasricha, Andrew Grigg, John Catalano, et al.
Leukemia & Lymphoma|May 9, 2008
A phase II study of liposomal daunorubicin, in combination with cyclophosphamide, vincristine and prednisolone, in elderly patients with previously untreated aggressive non-Hodgkin lymphomaPaul L R Mitchell, Paula Marlton, Andrew Grigg, et al.
British Journal of Haematology|July 22, 2014
A multi-centre, single-arm, open-label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R-ITP1000 study)Huyen Tran, Tim Brighton, Andrew Grigg, et al.
The Journal of Antimicrobial Chemotherapy|March 19, 2010
Pharmacoeconomic evaluation of voriconazole versus posaconazole for antifungal prophylaxis in acute myeloid leukaemiaDaoud Al-Badriyeh, Monica Slavin, Danny Liew, et al.
Annals of Hematology|February 17, 2016
Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern eraAzim Jalali, Francis J Ha, Geoff Chong, et al.
Leukemia & Lymphoma|July 26, 2016
Busulfan is effective second-line therapy for older patients with Philadelphia-negative myeloproliferative neoplasms intolerant of or unresponsive to hydroxyureaGenevieve Douglas, Claire Harrison, Cecily Forsyth, et al.
Annals of Hematology|July 28, 2018
The pharmacokinetics and pharmacodynamics of busulfan when combined with melphalan as conditioning in adult autologous stem cell transplant recipientsAbbey Willcox, Eric Wong, Christa Nath, et al.
Pageof 14